Longboard has a complementary product in late-stage development for Developmental and Epileptic Encephalopathies (DEEs), which is an area of high unmet medical need, the companies said.

Neuroscience specialist Lundbeck has agreed to buy Longboard Pharmaceuticals for $2.6 billion, expanding its pipeline with an epilepsy drug tipped as a future blockbuster. The Danish drugmaker has ...

patients with significant unmet medical needs,” said Kevin R. Lind, president and CEO of Longboard in the announcement. The local company is also developing a phase one treatment that seeks to ...